CLINICAL STUDY TO ASSESS THE EFFECT OF AMALAKI SYRUP AS IMMUNOMODULATER FOR LOWERING DOWN THE MORBIDITY RATE

Abstract

It h as been estimated that about 6 lak h s infant and young children die from RS V annually, and if bacterial co - infections are included then this number may approach 10 lak h s deaths annually. More than 2 million deaths are estimated to r esult each year in the world as a consequence of diarrheal disease in children of under five years. This statistic shows that children are more vulnerable to infection because their im mune system is less or under developed. Therefore, considering these pro spects a clinical trial was carried with 156 children (1 - 7 years of age group) suffering from recurrent diseases like cough, running nose, diarrhoea, fever etc. in three groups. These groups were assigned as Group A with A malaki syrup, group B with placebo syrup and group C with only observation. This clinical study prove s that a simple and cost effective formulation of A malaki is capable to bring down the morbidity status of children by the mechanism of immune modulation.